Telomerase Activity as a Marker for Differential Diagnosis of                     Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis

Gu, Huajian; Xin, Xiaoyan; Pan, Yaozhen; Zhang, Hong; Song, Tian; Sun, Chengyi

doi:10.5301/jbm.5000172

Cited by 6 publications

(4 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TA in CRC has been detected in a significant percentage of tumor samples, ranging from 80% to 100% [ 201 ], highlighting its role as a pivotal step in CRC carcinogenesis [ 202 ]. In contrast, TA has been found in normal mucosa samples at a lower frequency, ranging from 9% to 53% [ 22 , 203 ].…”

Section: Telomerase Activity and Crcmentioning

confidence: 99%

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis,

Chrysos,

Docea

et al. 2024

Cancers

View full text Add to dashboard Cite

Cancer of the colon and rectum (CRC) has been identified among the three most prevalent types of cancer and cancer-related deaths for both sexes. Even though significant progress in surgical and chemotherapeutic techniques has markedly improved disease-free and overall survival rates in contrast to those three decades ago, recent years have seen a stagnation in these improvements. This underscores the need for new therapies aiming to augment patient outcomes. A number of emerging strategies, such as immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT), have exhibited promising outcomes not only in preclinical but also in clinical settings. Additionally, a thorough appreciation of the underlying biology has expanded the scope of research into potential therapeutic interventions. For instance, the pivotal role of altered telomere length in early CRC carcinogenesis, leading to chromosomal instability and telomere dysfunction, presents a promising avenue for future treatments. Thus, this review explores the advancements in CRC immunotherapy and telomere-targeted therapies, examining potential synergies and how these novel treatment modalities intersect to potentially enhance each other’s efficacy, paving the way for promising future therapeutic advancements.

show abstract

Section: Telomerase Activity and Crcmentioning

confidence: 99%

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis,

Chrysos,

Docea

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…[170,[173][174][175][176] Therefore, high-quality, prospective, epidemiologic studies are needed to investigate the relationship between LTL and PDAC risk. Furthermore, telomerase activity has also been reported to be aberrantly increased in PDAC, [177][178][179] which could be a valuable marker in diagnosing PDAC.…”

Section: Metabolism Dysfunctionmentioning

confidence: 99%

Pancreatic adenocarcinoma and aging: understanding the menace for better management

Zhou

Jin

Hao

et al. 2023

Journal of Pancreatology

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is the leading cause of cancer-related death worldwide. As PDAC is more common in older adults and the population is aging, the incidence of pancreatic adenocarcinoma is expected to increase in the coming years. As a result, the mechanism and clinical management of PDAC in the elderly population is receiving more attention. This review will discuss age-related morphological and pathological changes, clinical management, surgery and adjuvant therapies, and molecular changes in elderly PDAC patients. More research is needed to clarify molecular mechanisms and develop new prevention and treatment strategies for PDAC in elderly patients.

show abstract

“…Human telomerase reverse transcriptase (hTERT), a major catalytic subunit of human telomerase, correlates well with telomerase activation and is involved in the uncontrolled proliferation of cancer cells by elongating telomeres that are normally lost during cell division. Telomerase activity is a promising diagnostic marker for PDAC and malignant IPMN, 84,91 and detection of hTERT expression in PJ by quantifying mRNA 83,84 and immunohistochemistry/cytology 85,86 has been performed with high sensitivity and specificity. S100P is a member of the S100 family that interacts with the receptor for advanced glycation end‐products, p53, and p21 and plays a role in the degradation of the extracellular matrix and metastasis; S100P also interacts with cytoskeletal proteins and the plasma membrane during pancreatic cancer progression and metastasis 29 .…”

Section: Molecular Assessment Of Pj For Pancreatic Diseasesmentioning

confidence: 99%

Molecular assessment of endoscopically collected pancreatic juice and duodenal fluid from patients with pancreatic diseases

Takano

Fukasawa

Enomoto

2022

Digestive Endoscopy

View full text Add to dashboard Cite

One concern associated with pancreatic diseases is the poor prognosis of pancreatic cancer. Even with advances in diagnostic modalities, risk stratification of premalignant lesions and differentiation of pancreatic cysts are challenging. Pancreatic lesions of concern include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystadenomas, pseudocysts, and retention cysts, as well as cystic degeneration of solid tumors such as solid pseudopapillary neoplasms and pancreatic neuroendocrine neoplasms. Pancreatic juice obtained during endoscopic retrograde cholangiopancreatography has previously been used for the detection of KRAS mutation. Recently, duodenal fluid, which can be obtained during the relatively minimally invasive procedures of endoscopic ultrasound (EUS) and esophagogastroduodenoscopy, and cyst fluid collected by EUS‐guided fine‐needle aspiration (FNA) were used for molecular biological analysis. Furthermore, advanced analytic methods with high sensitivity were used for the detection of single and multiple markers. Early detection of malignant pancreatic tumors and risk stratification of premalignant tumors can be performed using duodenal fluid samples with a single marker with high sensitivity. Technological advances in simultaneous detection of multiple markers allow for the differentiation of cystic pancreatic tumors. One thing to note is that the clinical guidelines do not recommend pancreatic cyst fluid and pancreatic juice (PJ) sampling by EUS‐FNA and endoscopic retrograde cholangiopancreatography, respectively, in actual clinical practice, but state that they be performed at experienced facilities, and duodenal fluid sampling is not mentioned in the guidelines. With improved specimen handling and the combination of markers, molecular markers in PJ samples may be used in clinical practice in the near future.

show abstract

Telomerase Activity as a Marker for Differential Diagnosis of Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis

Abstract: The present meta-analysis demonstrates that telomerase activity could be a useful biomarker for the differential diagnosis of pancreatic adenocarcinoma and benign pancreatic diseases.

Cited by 6 publications

References 65 publications

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Pancreatic adenocarcinoma and aging: understanding the menace for better management

Molecular assessment of endoscopically collected pancreatic juice and duodenal fluid from patients with pancreatic diseases

Contact Info

Product

Resources

About